Inhibikase Therapeutics, Inc. Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price
Inhibikase Therapeutics, Inc. (IKT) had Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price of $0.97 per share as of 2022-06-30, per its 10-Q filed 2022-08-12.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 · last filed 2022-11-14
- 2022-06-30: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $0.97.
- 2022-03-31: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $1.08.
- 2021-09-30: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $6.82.
- 2021-08-31: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $2.02.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2022-06-30 | $0.97 10-Q · filed 2022-08-12 |
| 2022-03-31 | $1.08 10-Q · filed 2022-05-16 |
| 2021-09-30 | $6.82 10-Q · filed 2021-11-15 |
| 2021-08-31 | $2.02 10-Q · filed 2021-11-15 |
| 2021-08-16 | $1.79 10-Q · filed 2021-11-15 |
| 2021-06-30 | $6.82 10-Q · filed 2022-11-14 |
| 2021-06-25 | $2.92 10-Q · filed 2021-11-15 |
| 2021-05-31 | $0.38 10-Q · filed 2021-11-15 |
| 2021-03-31 | $6.82 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |